The Adoption Gap in Healthcare (Part 3): The Economic Barrier
Economic Value Supersedes Everything Else
The economic barrier is the one most likely to be underestimated by marketing teams and overestimated by sales teams.
Marketing teams tend to assume that strong clinical evidence will carry the economic argument. Sales tends to believe that a compelling ROI model, presented to the right financial stakeholder, will close the gap. Both assumptions are incomplete.
The economic barrier in health system technology adoption is not simply about price. It is about the complex relationship between clinical value and financial value in institutions that are simultaneously mission and bottom-line driven. Understanding that tension and developing commercial strategies that address it is one of the most sophisticated challenges in healthcare marketing.
In healthcare, the person who benefits from a technology is rarely the person who pays for it. That disconnect is the root of almost every economic barrier.
The Reimbursement Gap
For diagnostics in particular, reimbursement is the economic bedrock on which everything else is built. A technology without a clear reimbursement pathway is asking health systems to absorb financial risk that most are unwilling and often unable to accept.
The reimbursement landscape for novel diagnostics is complex. Medicare coverage determinations, commercial payer policies, and value-based care contract structures each represent distinct economic environments. A technology that is well-reimbursed under Medicare fee-for-service may generate a very different economic case in a capitated, value-based arrangement where the value is derived from downstream cost avoidance rather than per-test revenue.
Marketing teams that wait for reimbursement clarity before engaging health systems miss the strategic window. The marketing team must identify early adopters who are willing to bet on technology even when the reimbursement path is not well-defined in the short term.
These institutions become partners in the adoption, implementation, and reimbursement journey because they can see around the corner and can play a long game.
The Budget Ownership Problem
Even when reimbursement is established, health systems face an internal economic barrier that is rarely discussed in commercial planning: budget ownership ambiguity. Who actually pays for a new diagnostic test or technology platform - the lab, the clinical department, the hospital, or the health system's central budget?
This question is not semantic. In large health systems with decentralized financial structures, a technology that benefits one department may be funded by another, creating political friction that no amount of clinical evidence can resolve on its own. I have seen compelling technologies stall for months at the contracting stage because no one could agree on which budget line it belonged to.
Commercial teams that map the internal financial architecture of their target health systems, understanding who controls the relevant budget, who influences it, and who must sign off, gain a significant advantage. This is not financial intelligence for its own sake. It is the foundation of a realistic commercialization strategy.
Economic modeling is not a finance function alone. I believe it is something that marketing leads and delivers that translates clinical outcomes into the language that moves budget decisions
Building the Value Dossier
The most effective economic tool in healthcare commercialization is to build a value dossier: a rigorously constructed, institution-specific document that translates clinical outcomes into financial language. Not generic ROI claims, but specific, modeled projections based on the health system's own patient volume, payer mix, current standard of care, and cost structure.
A strong value dossier addresses the economic questions that matter most to each stakeholder. For the CFO: what is the net financial impact over a 3-year horizon, accounting for reimbursement, implementation costs, and downstream utilization effects? For the CMO: what is the impact on patient outcomes metrics that affect value-based contract performance? For the department head: what is the per-test economics under the institution's current reimbursement environment?
Building this dossier requires collaboration between marketing, health economics, and medical affairs, and ideally involves the health system itself as a co-contributor, using its own data to model the projections. That co-creation process is not just analytically stronger. It is commercially powerful because it transforms the health system from a buyer into a stakeholder in the value narrative.
Training Commercial Teams to Speak CFO Language
One of the most consistent gaps I observe in healthcare commercial teams is the inability to bridge clinical and financial conversations within the same institution. Sales representatives who are fluent in clinical data are often uncomfortable in financial discussions. Marketing campaigns that lead with efficacy data lose the economic stakeholders entirely.
The solution is not to turn clinical specialists into financial analysts. It is to build commercial teams that include economic fluency as a core competency and to provide them with tools, training, and materials that make the financial conversation approachable. This includes health-system-specific ROI calculators, reimbursement guides tailored to different payer environments, and talking points that translate clinical outcomes into the financial metrics that health system executives actually track.
One note of caution - commercial teams are not reimbursement experts and therefore should only offer financial info as guidelines, so that the institutions can figure out their own specific paths.
Barrier Audit: Questions To Ask
Have you mapped the budget ownership structure of your priority accounts?
Do you have a value dossier that speaks to the CFO, CMO, and department head in their own language?
Are your commercial teams trained to navigate both clinical and financial conversations?
Have you identified the value-based care implications of your technology for different payment models/paths?
Do you have a clear reimbursement pathway narrative, and have you shared it proactively with target health systems?
Final in the series Part 4: The Operational Barrier. The unglamorous reality of what happens between contract signature and full deployment, and why commercial teams need to own it.